Related references
Note: Only part of the references are listed.Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells
Adam Goldman et al.
BLOOD (2023)
Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy
Nupur N. Uppal et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)
Engineered T Cells: CAR T Cell Therapy and Beyond
P. Connor Johnson et al.
CURRENT ONCOLOGY REPORTS (2022)
Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report
Tristan de Nattes et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2022)
Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases
Manqiqige Su et al.
AUTOIMMUNITY REVIEWS (2022)
Acute Kidney Injury in Critically Ill Patients with Cancer
Shruti Gupta et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)
Severe infections in recipients of cancer immunotherapy: what intensivists need to know
Adrien Joseph et al.
CURRENT OPINION IN CRITICAL CARE (2022)
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
Michele Fusaroli et al.
DRUG SAFETY (2022)
Acute Kidney Injury in Cancer Immunotherapy Recipients
Adrien Joseph et al.
CELLS (2022)
Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel
Meghan D. Lee et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
CAR T cells in solid tumors: challenges and opportunities
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
Giulia Bonaldo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies
Swetha R. Kanduri et al.
KIDNEY INTERNATIONAL REPORTS (2021)
Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study
Charles Dolladille et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Kathryn M. Cappell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma
Shruti Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
Victoria Gutgarts et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Correlation of IL-6 secretion and hyponatremia with the use of CD19+chimeric antigen receptor T-cells
Brianne N. Dixon et al.
CLINICAL NEPHROLOGY (2020)
Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance
Goeun Park et al.
LIFE-BASEL (2020)
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
Kitsada Wudhikarn et al.
BLOOD CANCER JOURNAL (2020)
Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data
Concetta Rafaniello et al.
PHARMACEUTICALS (2020)
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
Martina Pennisi et al.
BLOOD ADVANCES (2020)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Chimeric Antigen Receptor T Cell Therapy and the Kidney What the Nephrologist Needs to Know
Kenar D. Jhaveri et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Mark A. Perazella et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease
Karina Durlacher-Betzer et al.
KIDNEY INTERNATIONAL (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Chimeric antigen receptor T-cell therapies for multiple myeloma
Lekha Mikkilineni et al.
BLOOD (2017)
Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab
Debora Barbosa et al.
TRANSPLANTATION (2014)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Quantitative signal detection using spontaneous ADR reporting
A. Bate et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
A review of drug-induced hyponatremia
George Liamis et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)